产品说明
包装
5, 25 mg in glass bottle
生化/生理作用
PD166793 is a broad spectrum, but class-selective, MMP inhibitor (low nM at MMP-2 & 3 and low μM at MMP-1, 7 & 9). Adding PD166793 to the high-fat diet substantially reduced the rise in blood glucose. The improvement of glucose homeostasis in PD166793-treated ZDF rats was a result of the enhancement of β-cell function. It prevents β-cell dysfunction and diabetes in female ZDF rats on a high-fat diet. It has been shown to block left ventricular remodeling and dysfunction in a rat model of heart failure. Preservation of normoglycemia and normal glucose tolerance in compound PD166793-treated animals is accompanied by preservation of the high serum insulin levels that are a consequence of the insulin resistance present in these animals. It is not reversing insulin resistance these animals. The most striking effect of the compound is on pancreatic insulin content and β-cell volume.
特点和优势
This compound was developed by Pfizer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
基本信息
| 经验(实验)分子式 | C17H18BrNO4S · xH2O |
| 分子量 | 412.30 (anhydrous basis) |
| MDL编号 | MFCD12912437 |
| PubChem化学物质编号 | 329819997 |
| NACRES | NA.77 |
产品性质
| 质量水平 | 100 |
| 测定 | ≥98% (HPLC) |
| 形式 | solid |
| 创始人 | Pfizer |
| 储存温度 | 2-8℃ |
| SMILES string | O.CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c2ccc(Br)cc2)C(O)=O |
| InChI | 1S/C17H18BrNO4S.H2O/c1-11(2)16(17(20)21)19-24(22,23)15-9-5-13(6-10-15)12-3-7-14(18)8-4-12;/h3-11,16,19H,1-2H3,(H,20,21);1H2/t16-;/m0./s1 |
| InChI key | LUKRECOTGXWIDO-NTISSMGPSA-N |
| Gene Information |
安全信息
| 储存分类代码 | 11 - Combustible Solids |
| WGK | WGK 2 |
| 闪点(F) | Not applicable |
| 闪点(C) | Not applicable |
| 个人防护装备 | Eyeshields, Gloves, type N95 (US) |
